hpv vaccine – Page 2 – Oral Cancer News

HPV vaccine gains support of ADA

Source: Multi Briefs Date: October 24th, 2018 Author: Tammy Adams The American Cancer Society estimates there will be more than 50,000 new cases of oral cancer in 2018. And between 70 to 80 percent of these cases will be attributed to the human papillomavirus virus (HPV), a virus that has types associated with oropharyngeal cancer. These staggering numbers call for action; action the American Dental Society is willing to take. Why? Because the HPV vaccine could prevent the vast majority of these new cases, but compared to other vaccines in the U.S., it is underutilized. According to a resolution passed recently by the ADA House of Delegates, the ADA urges dentists to support the use and administration of the human papillomavirus virus vaccine, recognizing it as a way to help prevent infection of the types of HPV associated with oropharyngeal cancer. Resolution 53H-2018 cites recommendations from the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices. It states that the vaccination is a "safe and effective intervention to decrease the burden of oral and oropharyngeal HPV infection." The policy is the result of a multifaceted ADA council proposal that includes input from the Council on Scientific Affairs, the Council on Advocacy for Access and Prevention and the Council on Dental Practice. A workgroup committed to the HPV issue and led by ADA volunteer members developed an evidence-based background report to help write the policy. Dr. Paul Eleazer, past chair of the ADA Council on Scientific Affairs, said that [...]

Charlotte Parker2018-10-25T15:38:39-07:00October, 2018|Oral Cancer News|

Australia may become the first country to eliminate one form of cancer

Author: Brad Jones Date: March 8, 2018 Source: flipboard.com The International Papillomavirus Society has announced that Australia could become the first country to eliminate cervical cancer entirely. According to a new study, Australia's efforts to distribute a human papillomavirus (HPV) vaccine for free in schools have been a resounding success. The sexually transmitted infection causes 99.9 percent of cases of cervical cancer. In 2007, the Australian federal government began offering the vaccine to girls aged 12-13, and in 2013 it was made available to boys, too. Girls and boys outside of that age bracket but under nineteen are also entitled to two free doses of the vaccine. Between 2005 and 2015, the percentage of Australian women aged between 18 and 24 who had HPV dropped from 22.7 percent to just 1.1 percent. Immunization rates have increased further since 2015, contributing to what's being described as a "herd protection" effect. Coupled with a more advanced screening test that was introduced by the Australian government in December 2017, there are hopes that no new cases of cervical cancer will be reported within ten or twenty years. THE WORLD ISN'T CATCHING UP In the US, the HPV vaccine is not free. It can cost as much as $450 for the full regimen, according to the Association of Reproductive Health Professionals, although financial assistance is often available. In 2016, 78.6% of 15-year-old Australian girls, and 72.9% of 15-year-old Australian boys were vaccinated - but only 50% of American girls between 13 and 17, and 38% of American boys between 13 and [...]

Charlotte Parker2018-03-08T14:10:27-07:00March, 2018|Oral Cancer News|

ASCO Urges Aggressive Efforts to Increase HPV Vaccination

Source: www.medscape.comAuthor: Zosia Chustecka Human papillomavirus (HPV) vaccines have now been available for 10 years, but despite many medical professional bodies strongly recommending the vaccine, uptake in the United States remains low. Data from a national survey show that about 36% of girls and 14% of boys have received the full schedule of HPV vaccines needed to provide protection (Vaccine. 2013;31:1673-1679). Now the American Society of Clinical Oncology (ASCO) has become involved, and in a position statement issued today the organization calls for aggressive efforts to increase uptake of the HPV vaccines to "protect young people from life-threatening cancers." "With safe and effective vaccines readily available, no young person today should have to face the devastating diagnosis of a preventable cancer like cervical cancer. But unless we rapidly increase vaccination rates for boys and girls, many of them will," ASCO President Julie M. Vose, MD, said in a statement. "As oncologists, we see the terrible effects of these cancers first hand, and we have to contribute to improving today's alarmingly low vaccination rates," she added. The new policy statement is published online April 11 in the Journal of Clinical Oncology. The statement notes that HPV vaccination has been previously recommended by many US medical societies, including the American Cancer Society, the American College of Obstetrics and Gynecology Committee, the American Dental Association, the American Head and Neck Society, the American Nurses Association, the American Pharmacists Association, the Association of Immunization Managers, the Society for Adolescent Medicine, and the Society of Gynecologic Oncology. [...]

Charlotte Parker2016-04-18T13:12:04-07:00April, 2016|Oral Cancer News|

Study: HPV vaccine reduces HPV incidence in teenage girls

Source: www.upi.comAuthor: Stephen Feller Just over half of girls have received the HPV vaccination, but a new CDC study shows it has significantly reduced prevalence of the cancer-causing STI among females who have received the vaccine when compared with those who have not. Photo by Adam Gregor/Shutterstock WASHINGTON, Feb. 22 (UPI) -- The prevalence of human papillomavirus infection among teenage and young adult women is down nearly two-thirds since the U.S. Centers for Disease Control and Prevention started recommending vaccine in 2006, according to a new study. The study is the first to show a drop in prevalence among women in their 20s, and continues to show decreases seen in smaller studies during the last few years, but researchers say the effect could be much stronger. The vaccine is recommended by the CDC and other organizations for girls and boys starting at age 11, experts say, in order to protect children from HPV before they become sexually active and can become infected. Concerns that the vaccine would influence teens' sexual practices have also been unfounded, as research has shown the vaccine does not make children more likely to engage in risky sexual behavior, based on a the lack of an increase in other STI incidence among vaccinated girls. "It's just like putting on your seatbelt before turning on the car," Dr. Alix Casler, medical director of pediatrics for Orlando Health, told UPI. She suggests separating the adolescents' eventual discovery of sex from the effort to prevent life-threatening diseases. Recommendations [...]

Charlotte Parker2016-02-22T13:59:16-07:00February, 2016|Oral Cancer News|

HPV debate reframed to focus on cancer

January 27, 2016 By Dr. Rachel Tompa / Fred Hutch News Science U.S. cancer centers unanimously call for increase in vaccine use for cancer prevention. Amid recent talk of “moonshot” cancer cures and new treatments in development, it can be easy to forget that we already have an effective, simple way to prevent at least six types of cancer. It’s called the HPV vaccine and it protects people from infection with the strains of human papillomavirus responsible for causing nearly all cervical and anal cancers, as well as many other genital cancers and certain head and neck cancers. And it’s not getting used. The Centers for Disease Control and Prevention recommends that all adolescent boys and girls receive the three-dose vaccine series at age 11 or 12. But in 2014, only about 40 percent of eligible teenage girls and just over 21 percent of boys had received the full course, according to the CDC’s latest data. Now, all 69 National Cancer Institute-designated cancer centers are joining together to voice their frustration at the low uptake of the HPV vaccine — with the hope of refocusing the lens of the vaccination discussion on cancer prevention. Public debate about the vaccine — and, possibly, the low levels of vaccine use among adolescents — likely stems from the virus’ sexual transmission, said Fred Hutchinson Cancer Research Center virologist Dr. Denise Galloway. Galloway made critical discoveries linking HPV to cervical and other cancers and her laboratory helped lay the groundwork that made the vaccine’s [...]

Oral Cancer Foundation News Team - A2016-01-28T12:27:53-07:00January, 2016|Oral Cancer News|

Multisite HPV16/18 Vaccine Efficacy Against Cervical, Anal, and Oral HPV Infection

Source: www.oxfordjournal.comAuthors: Daniel Bleacher, Aimee Kreimer, Mark Schiffman, Rolando Herrero, Ana Cecilia Rodriguez, Douglas Lowy, Carolina Porras, John Schiller, Wim Quint, Silvia Jiminez, Mahboobeh Safaeian, Linda Struijk, John Scchussler, Allan Hildesheim, Paula Gonzalez Background: Previous Costa Rica Vaccine Trial (CVT) reports separately demonstrated vaccine efficacy against HPV16 and HPV18 (HPV16/18) infections at the cervical, anal, and oral regions; however, the combined overall multisite efficacy (protection at all three sites) and vaccine efficacy among women infected with HPV16 or HPV18 prior to vaccination are less known. Methods: Women age 18 to 25 years from the CVT were randomly assigned to the HPV16/18 vaccine (Cervarix) or a hepatitis A vaccine. Cervical, oral, and anal specimens were collected at the four-year follow-up visit from 4186 women. Multisite and single-site vaccine efficacies (VEs) and 95% confidence intervals (CIs) were computed for one-time detection of point prevalent HPV16/18 in the cervical, anal, and oral regions four years after vaccination. All statistical tests were two-sided. Results: The multisite woman-level vaccine efficacy was highest among “naïve” women (HPV16/18 seronegative and cervical HPV high-risk DNA negative at vaccination) (vaccine efficacy = 83.5%, 95% CI = 72.1% to 90.8%). Multisite woman-level vaccine efficacy was also demonstrated among women with evidence of a pre-enrollment HPV16 or HPV18 infection (seropositive for HPV16 and/or HPV18 but cervical HPV16/18 DNA negative at vaccination) (vaccine efficacy = 57.8%, 95% CI = 34.4% to 73.4%), but not in those with cervical HPV16 and/or HPV18 DNA at vaccination (anal/oral HPV16/18 VE = 25.3%, 95% CI = [...]

Charlotte Parker2015-10-16T10:10:13-07:00October, 2015|Oral Cancer News|

Single Dose of HPV-16/18 Vaccine Looks to Be Sufficient

Source: www.medscape.comAuthor: Jenni Laidman A single dose of a vaccine against human papillomavirus (HPV) may prevent cervical cancer as effectively as the standard three-dose regimen, researchers concluded after analyzing the combined results of two large vaccine trials. The HPV vaccine in these studies was Cervarix (GlaxoSmithKline), which is effective against HPV strains 16/18. If randomized controlled trials ultimately support the result of this post hoc analysis, it could broaden protection against cervical cancer in areas of the world where vaccination programs are hardest to administer and where cervical cancer is disproportionately burdensome, the study authors say. "Even if you ignore the expense, the feasibility of implementing and getting back to individuals for a second and third dose is quite challenging, especially in places where there is no infrastructure," coauthor Cosette Wheeler, PhD, Regents Professor, Pathology and Obstetrics and Gynecology, University of New Mexico Health Sciences Center in Albuquerque, told Medscape Medical News. The studies are published online June 10 in the Lancet Oncology. The possibility of a single-dose HPV vaccine is "a huge public health win," coauthor Aimée R. Kreimer, PhD, Investigator, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Bethesda, Maryland, told Medscape Medical News. "Even if one dose protects only against HPV types included in the vaccine formulation, if we vaccinated most girls, we would have the chance to reduce cervical cancer by around 75%." That's the exciting part, Dr Wheeler added. "If we're able to achieve success with one dose, or frankly even with two doses, that makes the possibility [...]

Oral Cancer Foundation News Team - A2015-06-15T12:33:51-07:00June, 2015|Oral Cancer News|

The Beginning of the End: Vaccine Prevention of HPV-Driven Cancers

Source: JNCI - Journal of the National Cancer Institute Anna R. Giuliano, Aimée R. Kreimer and Silvia de Sanjose + Author Affiliations Affiliations of authors: Center for Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL (ARG); Infections and Immunoepidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD (ARK); Cancer Epidemiology Research Programme, Catalan Institute of Oncology, IDIBELL, Spain (SdS); CIBER Epidemiologia y Salut Pública, Barcelona, Spain (SdS). Correspondence to: Anna R. Giuliano, PhD, Professor and Director, Center for Infection Research in Cancer, H. Lee Moffitt Cancer Center and Research Institute, MRC-CAN CONT, 12902 Magnolia Drive, Tampa, FL 33612 (e-mail: [email protected]). In this issue of the Journal, Saraiya and coauthors present an important analysis of human papillomavirus (HPV) detection in tumors retrieved from select US sites prior to HPV vaccine implementation (2006) (1). Not only are these data necessary to evaluate future vaccine effectiveness in reducing cancers caused by HPV infection, but they will also aid in the growing assessment of the worldwide burden of tumors attributable to HPV infection. These data raise the question: How many cases of cancer can be prevented by HPV vaccination in the United States? Twenty years ago, in 1995, the World Health Organization recognized for the first time that HPV 16 is the cause of cervical cancer. In 2005, 10 years after this report, there was sufficient accumulated evidence to state that HPV 16 is also the cause of multiple cancers in men and women, [...]

Oral Cancer Foundation News Team - A2015-05-11T13:33:23-07:00May, 2015|Oral Cancer News|

Katie Couric show on HPV vaccine sparks backlash

Source: CBS NewsPublished: Thursday, January 5, 2013By: Ryan Jaslow Katie Couric’s talk show "Katie" has drawn ire from doctors and journalists for a recent segment on the HPV vaccine that presented what it called “both sides” of the “HPV controversy.” The segment included personal stories from two moms who claim their daughters suffered serious harm from the vaccine (one of them died). In addition, the show featured two physicians: one who researched the vaccine and thinks its long-term protection benefits are oversold, and one who recommends it to her patients, in line with recommendations from the Centers for Disease Control and Prevention and the American Academy of Pediatrics. Ahead of the show, which aired Dec. 4, Couric tweeted: Dr. Arthur Caplan, director of the division of medical ethics at NYU Langone Medical Center in New York City, did not feel it was appropriate to juxtapose the anecdotal stories with the medical evidence. He had hoped more weight would be given to the scientific evidence of the vaccine’s safety profile and effectiveness at preventing cervical cancer. “The show was kind of inexcusable in terms of damage done versus positive contribution,” he told CBS News. Any time you’re vaccinating hundreds of thousands of people, Caplan said, you can expect that some people in that population will have health incidents occur. But their ailments may not necessarily be connected to the vaccine. What needs to be weighed is the cause and effect, versus what may be just coincidence. Mentioning such incidents in that [...]

Charlotte Parker2013-12-06T14:41:54-07:00December, 2013|Oral Cancer News|

The New Face of Oral Cancer

Source: nursing.advanceweb.comBy Jonathan BassettPosted on: April 22, 2013 For decades tobacco was the primary cause of oral cancer but a more insidious culprit has emerged. Jerry Wilck had no reason to suspect anything. Why would he? He only smoked for a couple of years and gave it up more than 40 years ago. He didn't drink excessively, didn't have a family history of cancer, and took good care of himself. In fact, maybe the only reason the 59-year-old consulted an oral surgeon about the small sore on his tongue - the result of a habit of running this particular spot along his teeth - was that there happened to be such a specialist right there in his office. Wilck was a general practice dentist in Langhorne, Pa., and particularly attuned to anomalies of the soft tissues of the mouth. His oral surgeon took no chances and ordered a biopsy. Wilck was "floored" the night in March 2005 when the lab report arrived by fax from the oral pathology department at Temple University in Philadelphia - squamous cell carcinoma. Wilck immediately consulted with John Ridge, MD, PhD, FACS, chief of head and neck surgery at Temple's Fox Chase Cancer Center. After surgical removal of part of his tongue and lymph nodes from his neck, along with a round of physical and speech therapy, Wilck is now cancer free and has full use of his jaw, throat and voice. "I was lucky," confessed Wilck, who retired from practice in 2009 and now spends a [...]

Charlotte Parker2013-06-10T12:26:21-07:00June, 2013|OCF In The News, Oral Cancer News|